Search

This study was conducted to evaluate the safety profile of Pantohematogen, a substance derived from the velvet antlers of the Altai Wapiti, which is commonly used as a functional ingredient in dietary supplements. In this clinical research, both male and female Wistar rats received the maximum tolerable intragastric dose of Pantohematogen. Over the course of six months, researchers monitored the animals for changes in general health status, body mass, hematologic and bone marrow parameters, and the functioning of major organs, including the liver, kidneys, heart, and brain.Throughout the experimental period, the animals exhibited stable behavior and maintained normal fur condition, appetite, reflex responses, and gastrointestinal and urinary tract function. No signs of a toxic response were detected following intragastric administration. However, administration of Pantohematogen at 250 and 500 mg/kg resulted in increased liver mass and reduced testicular size in male rats. This condition persisted for 2 weeks after treatment cessation. Other internal organs showed no abnormalities when compared with control and untreated animals.Importantly, the tested doses exceeded standard human-equivalent levels (per kilogram of body weight) by factors of 2, 10, and 20, respectively. Despite this, the findings indicated no evident toxicological impact from Pantohematogen exposure. This research was conducted at the Tomsk National Research Medical Center of the Russian Academy of Sciences under the supervision of Dr. N.I. Suslov, Doctor of Medical Science.

The administration of sorbents plays a vital role in reducing systemic toxicity after radionuclides or harmful chemicals enter the organism. This study explores the pharmacological characteristics of the newly developed ferrocyanide-bentonite sorbent, Ferbensorb. As a composite formulation, Ferbensorb integrates potassium-iron(III) hexacyanoferrate(II), bentonite, gelatin, along with a mixture of essential macro- and microelements. Experimental assessments were performed using mice and rats as animal models. The investigation evaluated its cesium sorption efficacy, strontium radionuclide retention capability, and performance under simulated associative mycotoxicosis. Autopsies were conducted to assess anatomical alterations, while variations in overall body mass and the condition of specific internal organs were documented. Blood analyses also included profiling of the leukocyte formula. The findings demonstrated that the ferrocyanide-bentonite sorbent, Ferbensorb, effectively alleviated both structural and functional disruptions induced by mycotoxins, including ochratoxin A, fumonisin B, and zearalenone. Improvements were observed in weight gain, innate immune response (indicated by a higher proportion of neutrophils), enhanced serum lysozyme and bactericidal activities, and increased survival rates in the treated animals.

This paper presents the findings of multiple investigations into the newly developed Bentorb sorbent, derived from winemaking byproducts, specifically the adhesive residues of yellow blood salt. Elemental analysis revealed that the predominant components of Bentorb include oxygen, carbon, silicon, aluminum, iron, nitrogen, and magnesium, which together make up the majority of the sorbent’s composition. Toxicological assessments of Bentorb were conducted using laboratory animals. To evaluate acute toxicity, 60 white mongrel rats, each weighing approximately 237 ± 7 g, were subjected to the substance. The results showed no significant changes in the general clinical condition of rats in either the experimental or control groups, and all animals survived the tests. Chronic toxicity was assessed in 60 white mice and 40 Wistar rats, each weighing 185 ± 12 g. Over the study period, no notable differences in health or survival rates were observed between the experimental and control groups. The effects of Bentorb on gastrointestinal function were examined in piglets aged 40-80 days. Additionally, the potential embryotoxicity of Bentorb was investigated in pregnant Wistar rats weighing 200-240 g. The study also included analyses of body weight and various internal organs in both control and experimental groups that received Bentorb.

Assessing erythrocyte acid resistance is a key part of understanding the effects of toxicants on the blood. The objective of this research is to examine both the isolated and combined effects of cadmium, lead, and zinc ions from contaminated drinking water on the acid resistance of erythrocytes in laboratory rats. This investigation was conducted in the Laboratory of Anatomy, Physiology, and Histology at Chechen State University in Grozny, Russia. The study used laboratory rats weighing 100-150 grams, bred in the university’s vivarium. Exposure to metals altered erythrograms, with a noticeable increase in the proportion of erythrocytes with lower resistance and a reduction in hemolysis time. The most considerable alterations were observed after prolonged exposure to Pb2+, Cd2+, Zn2+, and their mixture. After 30 days of exposure to these ions, the peak times for erythrograms were recorded as 0.5 minutes for Pb2+, 1.0 minutes for Zn2+, and 1.5 minutes for Cd2+. The percentage of erythrocytes undergoing hemolysis at these times was significantly higher, being three times more than the control for Pb2+ and Zn2+, and comparable to the control for Cd2+ (36%). Hemolysis times were notably shorter—2.5 minutes for Pb2+ and Zn2+, and 4.5 minutes for Cd2+. By the end of the 30 days, all rats in the heavy-metal exposure group had died. The findings indicate that prolonged exposure to heavy metals induces significant changes in the erythrocyte population and their acid resistance.

Some studies have highlighted the role of Janus kinase 3 (JAK3) in the development of various cancers. To manage this condition, inhibitors such as decernotinib and facitinib are commonly used, although these drugs can cause elevations in liver enzymes and increased lipid levels. It is essential to recognize that new therapies are being developed to inhibit cancer cell growth, using both theoretical and experimental approaches. This study aimed to investigate whether carbazole derivatives (1-25) could interact with JAK3, using the 3pjc protein, decernotinib, and facitinib as reference compounds in the DockingServer tool. The results showed that the carbazole analogs engage with different regions of the 3pjc protein compared to facitinib and decernotinib. Additionally, the inhibition constant (Ki) for carbazole-protein interactions with compounds 2, 5, 9, 17, 18, and 22 was lower than that of the reference drugs, suggesting that these carbazole analogs could be effective JAK3 inhibitors and may help reduce cancer cell growth.

For many years, various drugs have been utilized to treat different cancer types, but some of these treatments come with adverse effects such as liver damage, hypertension, and erectile dysfunction. In the pursuit of alternative therapeutic options, several new compounds have been developed to address this clinical challenge. Yet, the interactions of these compounds with biomolecules involved in cancer development remain largely unclear. With this context in mind, the present study aimed to explore the potential theoretical interaction of a series of pyrimidinone derivatives (compounds 1-27) with the X-linked inhibitor of apoptosis protein (XIAP), a key player in cancer progression, using the Docking model. The findings indicated that certain pyrimidinone derivatives (compounds 1-6, 10, 11, 14, 15, 22-24, 26, and 27) exhibited the ability to bind with the surface of the XIAP protein. In conclusion, these results suggest that some pyrimidinone derivatives may modulate XIAP’s biological activity, making them promising candidates for cancer therapy.

This investigation examined the bacterial profile and patterns of antibiotic resistance among cancer patients receiving care at B.P. Koirala Memorial Cancer Hospital in Bharatpur, Chitwan. Employing a hospital-based cross-sectional design, the study processed 384 clinical specimens obtained from cancer patients. Once bacterial growth was observed on selective and differential culture media, Gram staining was used as a preliminary identification method. Organisms were subsequently characterized based on their biochemical features, and antibiotic susceptibility testing was performed using the Kirby-Bauer disk diffusion technique. The results, measured by determining the diameter of the inhibition zones, adhered to the Clinical and Laboratory Standards Institute (CLSI) guidelines established in 2020. Data analysis was conducted using SPSS version 20.0.Among the 384 individuals included, 55.4% were male and 44.6% female. Bacterial growth was detected in 43.5% of the total specimens analyzed. A comparison between cancer types showed that hematogenous malignancies accounted for 40.7% of the positive cultures, while 45.5% were associated with non-hematogenous cancers. The most frequently isolated organism was Escherichia coli, making up 38.9% of isolates, followed by Klebsiella species (20.4%), Pseudomonas species (19.2%), Citrobacter species (9.0%), and Acinetobacter species (4.8%). Additionally, Staphylococcus aureus and Enterobacter aerogenes were detected in 3.6% and 3.0% of cases, respectively, while Proteus species and coagulase-negative Staphylococci (CoNS) accounted for 0.6% each. Regarding antibiotic resistance, E. coli demonstrated substantial resistance to amoxicillin (98.5%), followed by ciprofloxacin (73.9%) and cotrimoxazole (67.7%), whereas resistance to amikacin remained low. In contrast, S. aureus, the predominant gram-positive isolate, exhibited complete resistance (100%) to amoxycillin, ciprofloxacin, cloxacillin, and cephalexin (each at 66.7%), but remained fully sensitive to both Amikacin and Tigecycline. Overall, gram-negative bacteria were more frequently identified than gram-positive bacteria. The findings highlight the vulnerability of cancer patients to infections by opportunistic organisms, including multidrug-resistant (MDR) strains, underscoring the urgent need for robust antimicrobial stewardship and ongoing surveillance of antibiotic resistance trends.

The present investigation retrospectively examined the therapeutic impact of crizotinib in a cohort of patients diagnosed with ALK-positive metastatic lung cancer. A total of 25 individuals participated, and survival outcomes were assessed using Kaplan-Meier estimation and Cox proportional hazards modeling. Among the participants, 52% (13 patients) were male, and the mean age was 55 years, spanning from 30 to 80 years. Notably, 92% (23 patients) presented with de novo metastatic disease. Central nervous system involvement was observed in 32%, while 20% exhibited hepatic metastases. Before the administration of crizotinib, 64% had received systemic chemotherapy, and 20% underwent palliative radiation. The median progression-free survival was calculated at 16.8 months (95% CI: 5.7–27.9). Adverse effects of grade 1–2 severity were recorded in 36% of cases, whereas 12% experienced grade 3–4 toxicities. Upon disease progression, 52% (13 patients) transitioned to alternative therapies, including second-generation ALK inhibitors such as alectinib, ceritinib, or lorlatinib, or received additional chemotherapy. Median overall survival reached 44.2 months (95% CI: 28.5–59.9), with a 37.4% survival rate at the four-year mark. Multivariate analysis identified the ALK positivity ratio as a statistically significant prognostic variable for overall survival (P = 0.02). These results highlight the clinical benefit and tolerability of crizotinib in the management of ALK-mutant metastatic non-small cell lung cancer and reinforce the prognostic relevance of ALK positivity in predicting long-term survival.

Personalized medicine has transformed how disease risk, diagnosis, and therapeutic selection are conceptualised, yet the pharmaceutical products used to deliver many therapies remain comparatively static. In many clinical settings, personalization still means selecting a drug more precisely while administering it through conventional dosage forms. This creates a widening gap between diagnostic sophistication and pharmaceutical responsiveness. The prevailing interpretation of personalized pharmaceutics is often reduced to customized dosing. Dose adjustment is important, but it cannot by itself address fluctuating physiology, variable adherence, lifestyle change, disease progression, or treatment-emergent toxicity. A patient’s therapeutic need is not a fixed parameter but a moving target. This conceptual review reframes personalized pharmaceutics as the design of adaptive therapeutic systems. Such systems are not merely individualized at the point of prescription or manufacture; they sense, respond, and evolve with the patient over time. The central argument is that pharmaceutical technology must move from static customization toward dynamic therapeutic adaptation. The analysis shows that customized dosing addresses only one layer of patient variability, whereas adaptive therapeutic systems combine patient-specific design, feedback control, responsive materials, digital monitoring, and translational governance. Four tables clarify definitions, identify unresolved limits of dose-only personalization, describe representative adaptive systems, and map translation challenges. Together, these elements support a broader conceptual vocabulary for personalized pharmaceutics. Realising the full potential of personalized medicine requires pharmaceutical systems that co-evolve with the patient. The future of personalized pharmaceutics therefore depends not only on tailoring what dose is given, but on designing systems that can adapt when, how, where, and why therapy is delivered. This shift has implications for formulation science, device engineering, clinical trials, regulation, reimbursement, and patient participation.

Scalable drug delivery platforms are increasingly central to pharmaceutical innovation because they can shorten development timelines, support repeated product generation, and enable broader access when manufacturing and regulatory pathways are sufficiently stable. Yet the term “platform” is often applied before a technology has demonstrated repeatable transfer across products, indications, and production environments. This creates uncertainty about whether a delivery technology is truly mature or simply promising. Existing maturity concepts offer useful starting points but do not fully capture the pharmaceutical specificity of drug delivery platforms. Generic technology readiness models tend to emphasise proof of concept, whereas manufacturing readiness frameworks focus on production capability. Pharmaceutical platform maturity requires a broader view that also includes formulation robustness, patient-facing performance, quality system integration, regulatory precedent, and lifecycle adaptability. This article develops a conceptual model for defining and assessing pharmaceutical platform maturity in scalable drug delivery technologies. The proposed Pharmaceutical Platform Maturity Model integrates product-level, process-level, and regulatory-level maturity into a single interpretive framework. The model is designed to distinguish early innovation from repeatable platform capability. The model defines scalable delivery technology criteria, identifies maturity indicators across three interdependent dimensions, and proposes a five-level maturity scale ranging from concept to commoditised platform. Four tables support the argument by contrasting existing assessment frameworks, defining scalability criteria, summarising maturity indicators, and presenting the integrated maturity rubric. The model is intended as a strategic, analytical, and communicative tool. The article concludes that platform maturity should not be inferred from clinical success, manufacturing feasibility, or regulatory approval alone. A drug delivery platform becomes mature only when product performance, process control, and regulatory confidence co-evolve into a repeatable system. This integrated perspective can help developers, investors, regulators, and technology assessors evaluate scalable delivery technologies more consistently.

Generative artificial intelligence is becoming increasingly relevant to pharmaceutical formulation because it can propose compositions, excipient combinations, processing conditions, and optimisation trajectories that may not be obvious through conventional experimental design. These capabilities create the possibility of faster development, broader exploration of formulation space, and more systematic use of prior knowledge. Yet the same models that expand formulation creativity often operate through complex latent representations that are difficult to interpret. This creates a trust problem for both scientific and regulatory decision-making. The central problem is that an AI-generated formulation is not only a predicted technical solution but also a claim about product performance, manufacturability, and quality. If the rationale behind that claim cannot be explained, formulation scientists may struggle to convert model outputs into mechanistic understanding. Regulators may likewise find it difficult to assess whether the proposed formulation is supported by transparent evidence. Opaque formulation design therefore risks becoming a translational bottleneck rather than an innovation accelerator. This perspective develops a conceptual framework for dual-purpose explainability in AI-generated pharmaceutical formulation design. The framework is designed to serve two decision contexts simultaneously. Scientific decision-makers require explanations that clarify formulation logic, reveal influential variables, and support hypothesis generation. Regulatory decision-makers require explanations that are auditable, reproducible, uncertainty-aware, and connected to product quality and safety evidence. The article first defines the conceptual gap between existing AI formulation capabilities and explainability expectations. It then describes the logic of AI-generated formulation, identifies distinct scientific and regulatory explanation requirements, and analyses transparency barriers. The proposed framework integrates global model explanations, local formulation-specific explanations, mechanistic interpretation, uncertainty communication, and regulatory evidence packaging. Three tables summarise the gap analysis, explainability requirements, and framework architecture. The article concludes that explainability must be treated as a design requirement rather than a post hoc add-on to pharmaceutical AI. AI-generated formulation designs will become useful only when their rationale can be interrogated, documented, challenged, and connected to established principles of product and process understanding. A dual-purpose explainability framework can help move the field from black-box prediction toward transparent, accountable, and scientifically meaningful formulation intelligence.

Most drug delivery systems are still designed around simplified temporal assumptions, such as constant exposure, sustained release, or once-daily convenience. These assumptions have improved practicality and therapeutic coverage, but they do not fully address the fact that diseases, patients, and healthcare systems operate through changing rhythms. A drug release profile that is pharmacologically adequate in average terms may still be poorly timed in relation to disease activity, patient behaviour, or clinical workflow. The central problem addressed in this perspective is temporal misalignment. Disease processes may intensify during specific circadian, ultradian, or episodic windows, while patient routines shape when medicines are actually taken, tolerated, or forgotten. At the same time, care pathways impose their own operational schedules through clinic visits, infusion slots, monitoring intervals, refill cycles, and home-care routines. This article proposes therapeutic synchronization as a systems-theory framework for drug delivery design. Therapeutic synchronization is defined as the deliberate alignment of drug release profiles with three interdependent temporal dimensions: disease rhythm, patient behaviour, and care pathway rhythm. The framework shifts attention from drug release as an isolated pharmaceutical property to drug release as a control input within a wider therapeutic system. The article develops this framework through theoretical synthesis rather than new empirical data. It integrates concepts from chronopharmacology, chrono-tailored drug delivery, bioresponsive and programmable release systems, medication adherence science, digital monitoring, and systems approaches to healthcare design. The objective is to construct an original systems theory model that can guide future drug delivery research and translation. The proposed model argues that synchronized therapy requires tri-axial alignment. Drug release must be timed to pharmacodynamic need, compatible with patient routines and behavioural variability, and feasible within the operational rhythm of care delivery. Four tables support the theory by summarising misalignment consequences, synchronization logic, drug release design options, and the proposed systems model. Therapeutic synchronization offers a forward-looking paradigm for drug delivery systems. Rather than asking only whether a formulation can sustain exposure, the framework asks whether it can deliver the right exposure at the right biological, behavioural, and care-system moment. This shift may support safer, more effective, and more patient-centred therapies.

The pharmaceutical industry is entering a period of accelerated digital transformation, driven by real-time sensing, automation, digital twins, advanced analytics, and connected healthcare technologies. Yet this transformation remains uneven across the pharmaceutical value chain. Manufacturing systems, quality systems, distribution infrastructures, and patient-facing technologies often evolve as separate digital domains rather than as components of one connected cyber-physical enterprise. This fragmentation limits the capacity of pharmaceutical organizations to use data as a continuous operational resource. A manufacturing line may generate rich process data, a quality system may generate release decisions, a distribution network may generate environmental and traceability records, and a connected device may generate adherence or use data, but these signals are rarely integrated into a unified architecture. As a result, the industry remains only partially able to close the loop between product design, production, delivery, use, and real-world performance. The objective of this article is to propose an integrated cyber-physical system architecture that links pharmaceutical manufacturing, quality control, distribution, and patient use into a coherent technical framework. The proposed architecture treats the pharmaceutical product not only as a manufactured physical object but also as a data-linked therapeutic system. In this view, quality, traceability, and patient performance are co-produced through connected material, digital, and process flows. The article develops a systems-architecture perspective rather than an empirical study. It synthesises peer-reviewed literature on Pharma 4.0, continuous manufacturing, process analytical technology, digital twins, real-time release, blockchain traceability, cold-chain monitoring, smart packaging, connected drug delivery devices, and digital adherence monitoring. These domains are integrated into a four-layer architecture that connects factory operations to patient-facing use environments. The proposed framework defines four architectural layers: manufacturing, quality control, distribution, and patient use. It then specifies the data, material, and process flows required to connect these layers into a continuous cyber-physical loop. Five tables are used to clarify the architecture problem, the manufacturing layer, the patient-use layer, the end-to-end flows, and the proposed integrated architecture. A pharmaceutical cyber-physical system spanning from raw material to patient outcome represents a potential next frontier in drug product quality, supply chain resilience, and personalised therapy. Such a system would require coordinated action across manufacturers, technology providers, healthcare systems, regulators, and patients. Its value lies not only in automation, but in the creation of a connected pharmaceutical enterprise capable of learning from every stage of the product lifecycle.

Pharmaceutical manufacturing is moving from automated equipment and digitally assisted control toward more autonomous systems capable of interpreting process data, adjusting operating conditions, and supporting quality decisions. This trajectory promises faster response, improved consistency, and more adaptive control across complex production environments. Yet autonomy also changes the nature of manufacturing responsibility because technical decisions increasingly occur inside algorithmic systems rather than through visible human judgement alone. The central problem addressed in this article is the trust deficit created by autonomous pharmaceutical manufacturing. When an algorithm modifies a critical process parameter, detects an anomaly, recommends batch continuation, or contributes to a quality disposition, regulators, operators, quality units, and patients require confidence that the decision remains safe, explainable, reversible, and accountable. Trust cannot be assumed simply because the system performs well during validation; it must be sustained over time as processes, materials, sensors, models, and organisational practices evolve. This article develops an original theory-driven framework for trustworthy autonomous pharmaceutical manufacturing. The framework is structured around three interdependent pillars: human oversight, model drift management, and quality accountability. These pillars are treated not as separate compliance add-ons but as mutually reinforcing design requirements for autonomous manufacturing systems operating in Good Manufacturing Practice environments. The article draws on a theoretical synthesis of peer-reviewed literature on pharmaceutical manufacturing automation, process analytical technology, machine learning, trust in automation, human–autonomy teaming, resilience engineering, socio-technical systems, and model drift. It reframes autonomous manufacturing as a socio-technical trust problem rather than a purely technical optimisation problem. Four tables map the theoretical foundations, oversight architectures, drift-management logic, and integrated Trustworthy System Framework. The proposed framework argues that trustworthiness in autonomous pharmaceutical manufacturing is not a property of an algorithm alone. It emerges from the designed relationship among people, models, process controls, quality systems, audit trails, and governance responsibilities. Autonomous manufacturing will become viable only when the system can remain technically reliable, humanly overseen, and institutionally accountable throughout its lifecycle.

Pharmaceutical quality is often operationalized through stability testing, in which products are exposed to defined temperature and humidity conditions to support shelf-life assignment. This practice is indispensable, but it can create a narrow interpretation of quality when stability under controlled chamber conditions is treated as evidence of real-world performance. Products do not move through idealized chambers; they move through development uncertainty, manufacturing variability, distribution stress, and patient-level handling. This article argues that the dominant stability paradigm has encouraged a conceptual conflation between stability and robustness. Stability testing primarily asks whether a product remains within specification under predefined storage conditions for a defined period. Robustness, by contrast, asks whether the product–process–use system can continue to deliver acceptable quality when exposed to interacting stresses across the full lifecycle. The objective of this article is to develop an Integrated Robustness Theory for pharmaceutical products. The theory frames robustness as a system-level property spanning development, manufacturing, storage, and administration. It proposes that quality should be understood not only as shelf-life survival but also as resilient performance under realistic and combined stress conditions. The article critiques the limits of stability testing, defines robustness dimensions across lifecycle phases, and develops a systems-based framework for translating robustness into development strategy, manufacturing control, storage evaluation, and administration design. Three tables are used to map lifecycle robustness dimensions, storage stress gaps, and the integrated theory. The central conclusion is that pharmaceutical quality assurance must move beyond shelf-life thinking toward lifecycle robustness thinking.

Advanced drug delivery systems promise more precise, durable, and patient-centred therapy through nanomedicines, long-acting formulations, implantable platforms, smart delivery devices, and personalised dosage forms. These technologies can reduce dosing burden, improve therapeutic control, and expand the design space of pharmaceutical care. Yet the same sophistication that makes them attractive can also make them expensive, infrastructure-dependent, and difficult to use. The equity implications of these technologies therefore require systematic attention. The central problem addressed in this article is that pharmaceutical innovation is often evaluated through performance, safety, manufacturability, and market value, while equity remains treated as a downstream access issue. This creates a risk that advanced drug delivery systems will reach populations already well served by health systems while excluding communities facing poverty, geographic isolation, disability, low literacy, weak infrastructure, or limited digital access. Equity cannot be repaired only after launch if exclusion has already been built into the technology. It must be considered during design, development, evaluation, pricing, procurement, and implementation. This article develops the concept of pharmaceutical technology equity as a deliberate design and policy goal for advanced drug delivery systems. It argues that equitable pharmaceutical technology requires simultaneous attention to access, affordability, and usability. Access concerns whether the technology can physically and institutionally reach the people who need it. Affordability concerns whether patients and health systems can obtain it without unacceptable financial burden, while usability concerns whether diverse users can safely and effectively engage with the product in real settings. The article defines pharmaceutical technology equity, identifies structural barriers, and proposes design principles for inclusive advanced drug delivery systems. Four tables support the argument by defining equity logic, cataloguing access barriers, mapping design principles, and presenting a decision-oriented framework. The core conclusion is that equity must become an explicit and measurable goal of pharmaceutical technology development. Advanced drug delivery should not merely produce better products for privileged users; it should expand therapeutic capability for populations historically excluded from high-value innovation.

Drug delivery has become one of the most technically inventive areas of pharmaceutical science, producing increasingly elaborate platforms such as multifunctional nanoparticles, long-acting depots, 3D-printed dosage forms, implantable systems, and responsive materials. Yet the number of delivery technologies that successfully become routine clinical and commercial products remains small compared with the volume of experimental innovation. This mismatch creates a translational paradox at the centre of the field. This article argues that the paradox cannot be explained only by external barriers such as regulation, investment scarcity, or clinical conservatism. It also reflects an internal innovation logic that equates sophistication with value. In this logic, the most admired systems are often those with the most components, functions, triggers, layers, and claims of precision. The article develops an original critical theory of over-engineering in drug delivery. Over-engineering is defined as the addition of technical features, materials, control mechanisms, or architectural complexity beyond what is necessary for therapeutic function, manufacturability, usability, and economic viability. The central claim is that excessive complexity can reduce, rather than increase, translational probability. Through a critical theoretical synthesis of recent drug delivery and translational literature, the paper identifies mechanisms through which over-engineered systems become difficult to manufacture, characterise, regulate, finance, prescribe, and use. It argues that translational failure is not merely an unfortunate downstream event but is often designed into systems at the earliest conceptual stage. Complexity therefore becomes a hidden liability disguised as innovation. The article proposes a counter-logic of design simplification. This counter-logic does not reject sophisticated science, but it demands that sophistication be justified by translational necessity rather than aesthetic or academic appeal. The conclusion calls for a simplicity revolution in drug delivery, where the field learns to value robustness, manufacturability, usability, and patient access as highly as novelty.

Digital batch records have commonly been implemented as electronic substitutes for paper documentation, preserving the logic of retrospective compliance rather than transforming the logic of pharmaceutical knowledge. This narrow implementation view treats the batch record as a repository of completed events, signatures, deviations, and release evidence. Such a view is increasingly insufficient for manufacturing environments shaped by automation, continuous processing, process analytical technology, and real-time quality expectations. This article reconceptualises digital batch records as pharmaceutical knowledge systems rather than electronic documentation artefacts. The central argument is that a digital batch record should not merely record what occurred during manufacturing, but should structure why it occurred, how it relates to process understanding, and how it informs quality decisions. This reframing is especially important for continuous manufacturing, where batch boundaries, material histories, and quality evidence are dynamic rather than fixed. The objective of the article is to develop a conceptual systems perspective on digital batch records for continuous manufacturing and regulatory inspection. The article synthesises peer-reviewed literature on pharmaceutical digitalisation, continuous manufacturing, data integrity, knowledge management, process control, real-time release testing, and regulatory science. It does not present new empirical data, but constructs a conceptual model from existing evidence and emerging regulatory trends. The article defines the system boundary of digital batch records, explains their knowledge logic, connects them to pharmaceutical knowledge management, and positions them as infrastructure for continuous manufacturing and inspection transformation. It argues that digital batch records can integrate process data, material traceability, critical quality attributes, audit trails, deviation logic, and lifecycle knowledge into a structured manufacturing intelligence layer. Four tables are used to clarify the proposed record logic, continuous manufacturing integration, inspection transformation, and knowledge-system architecture. The article concludes that digital batch records should be designed as the cognitive infrastructure of pharmaceutical quality. When architected as knowledge systems, they can support real-time quality assurance, predictive process oversight, continuous improvement, and more transparent regulatory interaction. The shift from record-keeping to knowledge-driven assurance is therefore not a technical upgrade alone, but a transformation in how pharmaceutical manufacturing knows, governs, and demonstrates quality.

To evaluate patient-derived organoids as a translational testing platform for bio-nano drug delivery systems, this study examined whether organoid assays could predict therapeutic efficacy, identify organ-specific toxicity, and support patient-specific nanomedicine selection. The central objective was to determine whether tumor and matched normal organoids could resolve formulation-dependent differences that are often obscured in conventional two-dimensional cultures. Five bio-nano platforms, comprising lipid nanoparticles, polymeric micelles, gold nanorods, mesoporous silica nanoparticles, and liposomes, were systematically exposed to six patient-derived organoid lines representing colorectal, pancreatic, and lung cancer with matched normal intestinal, pancreatic, and airway organoids. High-content imaging, ATP-based viability testing, cleaved-caspase apoptosis quantification, confocal penetration mapping, epithelial barrier measurements, and cytokine profiling were performed. Organoid drug sensitivity scores were integrated with nanoparticle physicochemical attributes and genomic annotations. The organoid panel discriminated nanocarrier efficacy across tumor types, with targeted lipid nanoparticles and polymeric micelles producing the strongest selective tumor killing. Gold nanorods showed deep penetration but limited drug-release-associated efficacy, whereas mesoporous silica nanoparticles produced mixed efficacy with elevated inflammatory signaling in normal organoids. Personalized benefit-risk ranking identified different optimal nanocarriers for each patient-derived model, demonstrating clinically relevant interpatient heterogeneity. Organoid-based testing provides a scalable and patient-relevant strategy for evaluating bio-nano drug delivery systems before clinical translation. By combining efficacy, toxicity, penetration, and patient-specific sensitivity metrics, this platform may reduce late-stage nanomedicine failure and support individualized therapy selection.

Adaptive drug delivery has often been imagined as a technologically advanced system in which sensors, software, power sources, and feedback algorithms continuously monitor biological conditions and adjust therapy. This vision has stimulated important innovation, but it has also encouraged the assumption that adaptation requires electronic intelligence. In many pharmaceutical contexts, this assumption may unnecessarily increase complexity, cost, and technical fragility. A different design logic is possible. Dosage forms can respond to physiological environments through the intrinsic behavior of materials rather than through real-time electronic sensing. Such systems do not measure, calculate, or transmit information digitally; instead, they translate local biological conditions into physical or chemical changes that modulate drug release. This article develops a theory-driven framework for passive adaptive dosage forms. It distinguishes passive responsiveness from active sensor-driven feedback and defines adaptation as an emergent property of material–environment interaction. The framework is intended for non-electronic dosage forms that use physiological cues such as pH, enzymes, glucose, redox gradients, temperature, or mechanical stress to regulate release. The article synthesizes evidence and concepts from stimuli-responsive polymers, hydrogels, molecularly imprinted polymers, shape-memory systems, glucose-responsive platforms, and self-oscillating gels. It does not present new empirical data. Instead, it uses existing literature to clarify the design principles needed to treat passive responsiveness as a deliberate pharmaceutical strategy. Passive adaptive dosage forms offer a simpler and potentially more translatable route to adaptive therapy. Their promise lies not in replacing all electronic systems, but in expanding the adaptive delivery paradigm beyond sensors and circuits. By foregrounding material-based triggering and release behavior design, the article positions passive responsiveness as a distinct and underdeveloped class of pharmaceutical system design.

Drug delivery systems are often developed as bespoke technological solutions for a single molecule, route, indication, or patient group. This custom-build logic can generate highly sophisticated systems, but it also produces long development timelines, repeated formulation work, high translation costs, and limited scalability. As therapeutic pipelines become more diverse, this one-product–one-platform paradigm increasingly constrains the ability of pharmaceutical technology to respond efficiently to emerging clinical needs. The central problem addressed in this article is the absence of a formalised design principle for pharmaceutical modularity. Although modular behaviours can be observed in lipid nanoparticles, polymeric carriers, implantable systems, and three-dimensional printed medicines, these examples have not yet been unified into a coherent theory of reconfigurable delivery platform design. Without such a principle, modularity remains an implicit engineering convenience rather than an explicit pharmaceutical development strategy. This article proposes the Pharmaceutical Modularity Principle as a non-empirical theory for reconfigurable delivery platforms across molecules, diseases, and populations. The principle argues that delivery systems should be architected through a decoupled core-platform structure in which drug-specific, disease-targeting, release-modulating, and population-adaptation functions can be independently designed, validated, and substituted. The goal is not to eliminate product-specific optimisation, but to reduce unnecessary reinvention by defining which delivery functions can remain stable and which should remain reconfigurable. The proposed theory contributes a formal design vocabulary for platform-based pharmaceutical development. It reframes modularity as a disciplined architecture of functional partitioning, interface standardisation, module-level validation, and controlled reconfiguration. Future empirical work will be required to test whether the principle can reduce development time, support regulatory bridging, and enable adaptable product families without compromising quality, safety, or therapeutic performance.